2021
DOI: 10.1007/s12094-021-02685-8
|View full text |Cite
|
Sign up to set email alerts
|

Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

Abstract: Purpose Distal cholangiocarcinoma and pancreatic ductal adenocarcinoma are malignancies with poor prognoses that can be difficult to distinguish preoperatively. Thrombospondin-2 has been proposed as a novel diagnostic biomarker for early pancreatic ductal adenocarcinoma. The aim of the present study was to evaluate thrombospondin-2 as a diagnostic and prognostic biomarker in combination with current biomarker CA 19-9 for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
9
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(10 citation statements)
references
References 24 publications
0
9
0
Order By: Relevance
“…As far as inclusion of DOI and number of lymph node metastasis is concerned, the verdict is still out ( 29 32 ). There has, however, been increasing studies proposing revisions of the updated 8th edition and alternative staging systems for classification ( 33 37 ).…”
Section: Introductionmentioning
confidence: 99%
“…As far as inclusion of DOI and number of lymph node metastasis is concerned, the verdict is still out ( 29 32 ). There has, however, been increasing studies proposing revisions of the updated 8th edition and alternative staging systems for classification ( 33 37 ).…”
Section: Introductionmentioning
confidence: 99%
“…Of these, 28 studies met the eligibility criteria, reporting data on 6127 individuals (2770 patients with PDAC, 2082 healthy controls, and 1275 patients with benign disease). 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 Additionally, individual participant data from eight studies were obtained. 24 , 25 , 28 , 33 , 38 , 43 , 48 , 49
Fig.
…”
Section: Resultsmentioning
confidence: 99%
“… 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 Additionally, individual participant data from eight studies were obtained. 24 , 25 , 28 , 33 , 38 , 43 , 48 , 49
Fig. 1 Overview of the study selection process.
…”
Section: Resultsmentioning
confidence: 99%
“…NCOA1 is known to promote metastasis and angiogenesis in breast cancer [ 52 ], while HNPNPLL is able to suppress metastasis in colorectal cancer [ 53 ]. Furthermore, THBS2 has been proposed as novel diagnostic biomarker for early distal cholangiocarcinoma [ 54 ]. However, the glycosylation on them has not been fully explored.…”
Section: Resultsmentioning
confidence: 99%